News Details
23 June 2016

Horizon 2020 Funding (MOGLYNET)

The Kosterlitz Centre for Therapeutics is a partner in the Horizon 2020 MOGLYNET programme

The mission of MoGlyNet is to define a joint doctorate educational training model in Drug Discovery and Development where Academia and Industry, supported by other institutions/organizations, join their forces for:

  • Creating a common platform of knowledge and language for 12 early stage researchers (ESR) working in the Drug Discovery and Development area aiming to convey complementary Pharma-skills

  • Exploiting this platform to train a new generation of cutting-edge researchers and professionals highly attractive for employment by the European Pharma-industry and regulatory authorities

Establishing structures for long-term cooperation, strengthening the relationships among the leading Universities and Pharma-enterprises and to continuously develop the research training platform that European industry relies on

RESEARCH PROJECT

Atherosclerotic cardiovascular disease is the major cause of death in the western world. Thanks to cholesterol-lowering drugs, the lifespan and wellbeing of patients have been significantly improved. However, a large group of patients does not fully benefit from current lipid-lowering strategies.

Our multidisciplinary approach is focused on counteracting neovessel formation to prevent plaque rupture and its cardiovascular complications, thus leading to a more effective therapy for atherosclerosis

The MoGlyNet consortium is strongly multidisciplinary and takes advantage of a number of different state-of-the-art technologies and methodologies:

  • Computational chemistry and synthesis

  • Bioanalytics and biophysics

  • In vitro  and  in vivo biological evaluation

  • Imaging

  • Metabolomic and Proteomic studies

  • Oxidative stress studies


back



In This Section

Search News

Search News

Browse by Month

2017

2017

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

2016

2015

2014

2013

2012

2011

2010